Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.35), $0.05 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $5.95 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.